Dysmenorrhea treatment market volume analysis, segments, value share and key trends 2016 2026 (taj p

S AT P R E S S RELEASES

HOME

Submit the press release

Our Team & Contact

Gabriel L. Sardi, MD

PDFmyURL lets you convert a complete website to PDF automatically!

J A N U A R Y 1 9 , 2 0 1 7 B Y A B H I S H E K B U D H O L I YA

Dysmenorrhea Treatment Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026 Dysmenorrhea is a medical terminology used for menstrual pains in which the female encounters severe cramps in her lower abdomen which may extend to the lower legs and back. Most women begin having dysmenorrhea during adolescence, usually within four to five years of first menstrual period. Prostaglandins are chemicals that are formed in the lining of the uterus during menstruation. These prostaglandins cause muscle contractions in the uterus, which cause pain and decrease blood flow and oxygen to the uterus. A wide variety of underlying condition can contribute to menstrual disorders. To pinpoint the cause, physician generally rely on the patient’s medical history, physical examination, and laboratory test. This determines the exact cause of menstrual disorder and helps the physician to plan appropriate treatment. This has grabbed the attention of dysmenorrhea drug manufacturers to develop and commercialize more effective medicines to treat dysmenorrhea.

Dysmenorrhea Treatment Market: Drivers and Restraints

PDFmyURL lets you convert a complete website to PDF automatically!

S EA RCH

Search ‌

Submit the press release now!

Increasing incidence of dysmenorrhea, high awareness level and growing concern about dysmenorrhea among females from developed countries, involvement of companies for developing innovative drugs, and government campaigns with respect to women healthcare are effectively endorsing the growth of dysmenorrhea treatment market. However, side effect and complications of long term treatment, substantial morbidity of dysmenorrhea which leads to inadequate treatment, and traditional values of families would hinder the growth of dysmenorrhea treatment market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sa mple/rep-gb-1312 Dysmenorrhea Treatment Market: Segmentation The global dysmenorrhea treatment market is segmented based type of disease, and therapeutic class.

Based type of diseases, the global dysmenorrhea market is segmented into the following: Primary dysmenorrhea Secondary dysmenorrhea Endometriosis Adenomyosis Uterine myomas Endometrial polyps Cervical stenosis Obstructive malformations of genital tract PDFmyURL lets you convert a complete website to PDF automatically!

R EC E N T P O S T S

Lion Gem Luxembourg 3 Sarl PIK annonce ses

Based on therapeutic class, the global dysmenorrhea treatment market is segmented into the following:

résultats du quatrième trimestre et ses résultats

Non-hormonal medical treatment Non-steroidal anti-inflammatory drugs (NSAIDs) Non-selective NSAIDs

New Report of Chronic Obstructive Pulmonary

COX-2 inhibitors Transdermal glyceryl trinitrate Over-the-counter (OTC) medications

annuels pour l'exercice 2016.

January 27, 2017

Disease Drugs Industry Overview, Manufacturing Cost Structure Analysis, Growth Opportunities & Restraints to 2021 January 27, 2017

Lion Gem Luxembourg 3 Sarl PIK gibt Ergebnisse

Hormonal medicine treatment Combined oral contraceptive

für das vierte Quartal und das gesamte

Progestin regimens Levonorgestrel intrauterine system (LN-IUS) Surgical options

January 27, 2017

Geschäftsjahr 2016 bekannt

RBC Bearings to Webcast Third Quarter Fiscal Year 2017 Results Earnings Conference Call

Laparoscopy Hysterectomy Presacral neurectomy

February 8th

Laparoscopic uterosacral nerve ablation (LUNA) Intrauterine device (IUD)

Tomography Industry Research Report: Size,

January 27, 2017

Latest In-depth Dental Cone Beam Computed Share, Growth, Trends and Forecast 2021 January 27, 2017

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb1312

$18.02 Billion Drone Services Market by Industry, Application , Type of Drone, Duration of Service, and Region – Global Forecast to 2022 – Research and Markets

Dysmenorrhea Treatment Market: Overview By non-hormonal medical treatment, NSAID’s such as Ibuprofen and Naproxen, are most commonly used drugs for the treatment of dysmenorrhea and hold prominent share owing to its lower cost and easy availability. COX-2 inhibitors have also proven effective in PDFmyURL lets you convert a complete website to PDF automatically!

January 27, 2017

Atlantic Capital Bancshares, Inc. Reports Fourth Quarter 2016 Results January 27, 2017

AES Announces Fourth Quarter & Full Year 2016 Financial Results Conference Call to be Held on

relieving pain, and would gain prominence in developed countries.

Physicians also prescribe hormonal medicine treatment such as contraceptive pills to regularize the menstrual bleeding will gain good market share in emerging countries.

Monday, February 27, 2017 at 9:00 a.m. EST January 27, 2017

New Report of Endometriosis Drugs Industry Overview, Manufacturing Cost Structure Analysis, Growth Opportunities & Restraints to 2021

Dysmenorrhea Treatment Market: Region-wise Outlook Geographically, the North America accounts for the largest market share followed by Europe, in terms revenues and research activities. In addition. APEI market is also expected to grow significantly in the coming years owing to support of government and non-profit organizations in awareness campaigns, growing number of patients suffering with dysmenorrhea, and high disposable income.

Dysmenorrhea Treatment Market: Key Players Key companies operational in dysmenorrhea treatment market are Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, Terramedic, Inc., and others.

G O O G L E N E W S, S A T P R N E W S A B L A T I O N , DY S M E N O R R H E A T R E A T M E N T M A R K E T, P R I M A R Y , S YS T EM

PDFmyURL lets you convert a complete website to PDF automatically!

January 27, 2017

TCF Reports Quarterly Net Income of $50.1 Million, or 27 Cents Per Share and Annual Net Income of $212.1 Million, or $1.15 Per Share January 27, 2017

PREVI O US

Pa llets Ma rket to Register a Strong Growth By 2020

NEXT

2017 Prediction Electronic Equipment Repa ir Service Ma rket – Innova tion Efforts & Technologica l Adva ncements in the Electronics Industry

Proudly powered by WordPress

PDFmyURL lets you convert a complete website to PDF automatically!